Abstract
Hyperactive and damaging inflammation is a hallmark of severe rather than mild COVID-19 syndrome. To uncover key inflammatory differentiators between severe and mild COVID-19 disease, we applied an unbiased single-cell transcriptomic analysis. We integrated a bronchoalveolar lavage (BAL) dataset with a peripheral blood mononuclear cell dataset (PBMC) and analyzed the combined cell population, focusing on genes associated with disease severity. Distinct cell populations were detected in both BAL and PBMC where the immunomodulatory long non-coding RNAs (lncRNAs) NEAT1 and MALAT1 were highly differentially expressed between mild and severe patients. The detection of other severity associated genes involved in cellular stress response and apoptosis regulation suggests that the pro-inflammatory functions of these lncRNAs may foster cell stress and damage. The lncRNAs NEAT1 andMALAT1 are potential components of immune dysregulation in COVID-19 that may provide targets for severity related diagnostic measures or therapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by F30HL151182 (KH), T32HL144909 (CV), R01HL138628, and U01AI132898. No other payment or services were received from a third party for any aspect of this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work utilized publicly available deidentified data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This revision includes new sections highlighting validation data that further reinforces the conclusions of the original submission. Additional supplemental data is provided.
Data Availability
Data for BAL and PBMCs were downloaded from the NCBI Gene Expression Omnibus (accession number GSE145926) and the COVID-19 Cell Atlas (https:/www.covid19cellatlas.org/#wilk20), respectively. Data for validation was donwloaded from the following sources: nasopharyngeal validation - EGAS00001004481 (data downloaded from https://doi.org/10.6084/m9.figshare.12436517), and PBMC validation - EGAS00001004571(downloaded from https://beta.fastgenomics.org/datasets/detail-dataset-952687f71ef34322a850553c4a24e82e#Files)
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926
